Piramal Pharma Ltd (NSE: PPLPHARMA), a leading global pharmaceutical and life sciences company headquartered in Mumbai, reported its financial results for the third quarter (Q3) of the fiscal year ending December 31, 2025, on January 29, 2026. The quarter\u2019s performance reflects a mix of operational challenges alongside areas of resilient execution, underscoring the cyclical nature of the pharmaceutical services industry and the company\u2019s ongoing strategic recalibrations.<\/p>\n\n\n\n
On a consolidated basis, Q3 FY26 revenue from operations declined to \u20b92,140 crore, a decrease of approximately 3 percent compared with \u20b92,204 crore in Q3 FY25. The year-on-year contraction in revenue largely stemmed from softer demand in the Contract Development and Manufacturing Organisation (CDMO) segment\u2014down about 9 percent\u2014as clients adjusted inventories and early-stage order inflows remained muted in the first half of the fiscal year. EBITDA for the quarter also contracted significantly, falling 32 percent to \u20b9239 crore, with EBITDA margins narrowing to roughly 11 percent from 16 percent in the prior period. After accounting for exceptional items, the company reported a consolidated net loss of \u20b9136 crore in Q3 FY26, a marked reversal from a modest profit in the same quarter last year.<\/p>\n\n\n\n
Segmental performance for the quarter highlighted divergent trends within Piramal Pharma\u2019s portfolio. The CDMO business, which remains a core driver of scale, saw contraction due to destocking by a key on-patent product customer and a slower pace of new order inflows, attributable in part to uneven recovery in biopharma funding and regulatory delays in certain markets. In contrast, the Complex Hospital Generics (CHG) segment delivered modest growth, with a small uptick in revenue year-on-year, and the Proprietary and Consumer Healthcare (PCH) unit posted double-digit revenue gains, reflecting steady demand for niche product offerings.<\/p>\n\n\n\n
The substantial decline in EBITDA and contraction of margins indicate intensified pricing and cost pressures across the consolidated operations. A combination of volume softness in core segments and one-time exceptional charges\u2014such as impacts from new labour code adjustments\u2014compressed profitability. Margins in the CDMO segment, which typically exhibit higher operating leverage, were particularly affected as topline contraction outpaced cost absorption, leading to broader margin erosion.<\/p>\n\n\n\n
It is noteworthy that on a standalone basis, Piramal Pharma\u2019s reported net profit exhibited a positive year-on-year trend, with net profit rising by around 8.5 percent to \u20b9129 crore. Standalone revenue parallels this resilience, showing modest sequential improvement, albeit still lower than the prior year. The discrepancy between standalone profitability and consolidated losses highlights the impact of group-level items, including subsidiary performance and exceptional adjustments, reinforcing the need for careful interpretation of results across reporting layers.<\/p>\n\n\n\n
Despite near-term earnings pressures, Piramal Pharma\u2019s management has pointed to early signs of recovery in order flows since late 2025 and is advancing strategic investments aimed at long-term growth. Notable actions include the acquisition of the Kenalog\u00ae brand to enhance its generics portfolio and investments in capacity expansion in key markets. These moves signal a focus on product diversification and capability expansion even as industry headwinds persist. <\/p>\n\n\n\n
Piramal Pharma\u2019s Q3 FY26 results encapsulate a transitional phase marked by cyclical demand fluctuations, margin contraction, and strategic repositioning. While consolidated earnings were pressured by external and operational factors, the company\u2019s underlying business segments continue to demonstrate pockets of resilience. The company\u2019s emphasis on portfolio strengthening and judicious capacity investments positions it to navigate current challenges while laying foundations for future growth.<\/p>\n","protected":false},"excerpt":{"rendered":"
Piramal Pharma Ltd (NSE: PPLPHARMA), a leading global pharmaceutical and life sciences company headquartered in Mumbai, reported its financial results for the third quarter (Q3) of the fiscal year ending December 31, 2025, on January 29, 2026. The quarter\u2019s performance reflects a mix of operational challenges alongside areas of resilient execution, underscoring the cyclical nature […]<\/p>\n","protected":false},"author":2391,"featured_media":178299,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941],"tags":[13404,10169,14492,8157,8150,11950,9138,14986,10089],"class_list":["post-178298","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","tag-drugs","tag-earnings","tag-financial-results","tag-healthcare","tag-life-sciences","tag-medicine","tag-pharma","tag-piramal-pharma","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/piramal.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":148298,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-q4fy23-earnings-story\/","url_meta":{"origin":178298,"position":0},"title":"Piramal Pharma Q4FY23 Earnings Story","author":"Karan_Singh","date":"June 2, 2023","format":false,"excerpt":"Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Financial Results: Piramal Pharma Ltd. reported Total Income for Q4FY23 of \u20b9 2,188 Crores\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":151233,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-ltd-q1fy24-18-rise-in-revenue\/","url_meta":{"origin":178298,"position":1},"title":"Piramal Pharma Ltd Q1FY24; 18% rise in Revenue","author":"Karan_Singh","date":"August 4, 2023","format":false,"excerpt":"Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-187.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-187.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-187.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-187.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-187.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-187.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167311,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-ltd-q3fy25-64-fall-in-profits\/","url_meta":{"origin":178298,"position":2},"title":"Piramal Pharma Ltd Q3FY25; 64% fall in Profits","author":"Chirag Gupta","date":"March 10, 2025","format":false,"excerpt":"Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/3-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/3-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/3-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/3-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/3-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/3-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162416,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-ltd-q4fy24-102-rise-in-profits\/","url_meta":{"origin":178298,"position":3},"title":"Piramal Pharma Ltd Q4FY24; 102% rise in Profits","author":"Chirag Gupta","date":"June 21, 2024","format":false,"excerpt":"Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-191.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-191.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-191.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-191.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-191.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-191.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165295,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-ltd-q2fy25-360-rise-in-profits\/","url_meta":{"origin":178298,"position":4},"title":"Piramal Pharma Ltd Q2FY25; 360% rise in Profits","author":"Chirag Gupta","date":"October 29, 2024","format":false,"excerpt":"Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/download-2-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/download-2-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/download-2-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/download-2-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/download-2-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/download-2-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163477,"url":"https:\/\/alphastreet.com\/india\/piramal-pharma-ltd-q1fy25-12-rise-in-revenue\/","url_meta":{"origin":178298,"position":5},"title":"Piramal Pharma Ltd Q1FY25; 12% rise in Revenue","author":"Chirag Gupta","date":"August 1, 2024","format":false,"excerpt":"Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2391"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178298"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178298\/revisions"}],"predecessor-version":[{"id":178300,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178298\/revisions\/178300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/178299"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}